Show simple item record

dc.contributor.authorLawford, B.
dc.contributor.authorBarnes, M.
dc.contributor.authorSwagell, C.
dc.contributor.authorConnor, J.
dc.contributor.authorBurton, S.
dc.contributor.authorHeslop, Karen
dc.contributor.authorVoisey, J.
dc.contributor.authorMorris, C.
dc.contributor.authorNyst, P.
dc.contributor.authorNoble, E.
dc.contributor.authorYoung, R.
dc.date.accessioned2017-01-30T11:39:28Z
dc.date.available2017-01-30T11:39:28Z
dc.date.created2013-01-17T20:00:23Z
dc.date.issued2013
dc.identifier.citationLawford, B.R. and Barnes, M. and Swagell, C.D. and Connor, J.P. and Burton, S.C. and Heslop, K. and Voisey, J. and Morris, C.P. and Nyst, P. and Noble, E.P. and Young, R.M. 2013. DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. Journal of Psychopharmacology. 27 (4): pp. 343-348.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/13792
dc.identifier.doi10.1177/0269881112463469
dc.description.abstract

Although the advent of atypical, second-generation antipsychotics (SGAs) has resulted in reduced likelihood of akathisia, this adverse effect remains a problem. It is known that extrapyramidal adverse effects are associated with increased drug occupancy of the dopamine 2 receptors (DRD2). The A1 allele of the DRD2/ANKK1, rs1800497, is associated with decreased striatal DRD2 density. The aim of this study was to identify whether the A1(T) allele of DRD2/ANKK1 was associated with akathisia (as measured by Barnes Akathisia Rating Scale) in a clinical sample of 234 patients who were treated with antipsychotic drugs. Definite akathisia (a score ≥ 2 in the global clinical assessment of akathisia) was significantly less common in subjects who were prescribed SGAs (16.8%) than those prescribed FGAs (47.6%), p < 0.0001. Overall, 24.1% of A1+ patients (A1A2/A1A1) who were treated with SGAs had akathisia, compared to 10.8% of A1- (thus, A2A2) patients. A1+ patients who were administered SGAs also had higher global clinical assessment of akathisia scores than the A1- subjects (p = 0.01). SGAs maintained their advantage over FGAs regarding akathisia, even in A1+ patients who were treated with SGAs. These results strongly suggested that A1+ variants of the DRD2/ANKK1 Taq1A allele do confer an associated risk for akathisia in patients who were treated with SGAs, and these variants may explain inconsistencies found across prior studies, when comparing FGAs and SGAs.

dc.publisherSage Publications
dc.subjectANNK1
dc.subjectside effects
dc.subjectdrug types
dc.subjectAkathisia
dc.subjectgenetic association
dc.subjectantipsychotic drugs
dc.subjectdopamine 2 receptor
dc.titleDRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia
dc.typeJournal Article
dcterms.source.startPage1
dcterms.source.endPage6
dcterms.source.issn14617285
dcterms.source.titleJournal of Psychopharmacology (Psychopharm)
curtin.department
curtin.accessStatusFulltext not available


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record